Dose Adjustment Criteria Sample Clauses

Dose Adjustment Criteria. During the treatment period, participants will be able to receive IP as long as there are no dose limiting safety/tolerability concerns. Participants who cannot tolerate 50 mg will receive 40 mg for the remainder of the treatment period. If dose adjustment is deemed necessary by the investigator at any time during the treatment period, the participant will return to the site to return any remaining IP and for the adjusted dose to be dispensed. At the discretion of the investigator, participants who cannot tolerate the 40-mg dose will be discontinued from IP (refer to Section 8.4.1 for procedures for early IP discontinuation). Participants are encouraged to continue to come in for assessments following IP discontinuation.
Sample 1
AutoNDA by SimpleDocs
Dose Adjustment Criteria. During the Treatment Period, subjects will be able to receive study drug as long as there are no dose-limiting safety/tolerability concerns. Subjects who cannot tolerate 30 mg QD will receive 20 mg QD for the remainder of the Treatment Period. Subjects who experience intolerable AEs at the 20 mg QD dose level may be discontinued from study treatment at the discretion of the Investigator. Dose adjustments will be made based on tolerability as assessed by occurrence of a severe AE or a moderate AE of special interest (sedation, somnolence, dizziness, euphoric mood, confusion, drowsiness, inebriation (feeling drunk), or fatigue) judged by the investigator to be related to study drug. If a dose adjustment is deemed necessary by the Investigator at any time during the treatment period, the subject will return to the site to return any remaining current dose and for the adjusted dose to be dispensed.
Sample 1
Dose Adjustment Criteria. 7.4.1. Safety Criteria for Adjustment or Stopping Doses Dosing regimens for TSR-042, bevacizumab, and niraparib are described in Section 7.1. The rationale for the starting doses of TSR-042 and niraparib is provided in Section 5.1.4.2; the rationale for weight- and platelet-based dosing for niraparib is provided in Section 5.1.2.2 of the master protocol. Unless otherwise indicated, treatment with each combination agent will continue independent of dose adjustments, interruptions, or discontinuation of treatment for other combination agents.
Sample 1
Dose Adjustment Criteria. LJPC-501 dose may be titrated to achieve an age-, size-, and disease-appropriate MAP, which should remain above baseline, but less than 90 mmHg. Throughout treatment, LJPC-501 dose may be decreased to a minimum of 1.25 ng/kg/min and increased to a maximum rate of 40 ng/kg/min. If MAP exceeds 90 mmHg, SOC vasopressors should be down-titrated first, then LJPC-501 should be down-titrated if MAP remains ≥ 90 mmHg. Any decision to increase the dose rate above 40 ng/kg/min must be made in consultation with Sponsor. With Sponsor approval, the dose rate may be increased to a maximum of 80 ng/kg/min. Dose titration guidelines are provided in Section 8.3.2.
Sample 1
Dose Adjustment Criteria. The Safety Review Team will review safety parameters after the first subject in each cohort has completed Visit Day 7. The remaining 2 subjects in the cohort will receive the same dose if neither the safety criteria for adjusting or stopping doses (Section 4.4.1) nor the criteria for study termination (Section 4.5) preclude their treatment. When all subjects in the cohort have completed Visit Day 28, the Safety Review Team will again evaluate the safety parameters. If the safety criteria for adjusting or stopping doses and the criteria for study termination are not met, the first subject in the next cohort will receive the next higher RBM-007 dose level. The same treatment sequence and interval safety evaluations will be performed for each cohort.
Sample 1
Dose Adjustment Criteria. ‌ If a subject refuses the initial treatment or retreatment, the investigator must report the visit number, visit date, target SK number(s) that the subject refused to allow treatment for and the reason for the refusal in the subject’s CRF. If the subject’s refusal is associated with an AE, the investigator must also report the event on the appropriate CRF. The subject must have the Visit 2 initial study medication treatment to all target SKs to remain in the study. The subject does not need to be removed from the study based solely on her/his refusal to have a study medication retreatment at Visit 5 or Visit 7. Table 3: Study Design and Schedule of Assessments Visit Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 Visit 8 Visit 9 Visit 10 Visit 11 Treatment Day Day -13 - 0 Day 1 Day 2 Day 8 Day 15 Day 22 Day 29 Day 36 Day 57 Day 85 Day 113 Visit Window N/A N/A N/A ± 1 day ± 1 day ± 1 day ± 1 day ± 1 day ± 7 days ± 7 days ± 7 days Informed Consent X Inclusion/ Exclusion1 X X Subject Identifier2 X Dermatological Medical History X Demographics X Xxxxxxxxxxx Skin Type Assessment3 X Vital Signs4 X X X X X X Prior Medications/Therapies5 X Target and Non-Target SK Identification6 X Physician’s Lesion Assessment7 X X X X X X X X SK Dimensions8 X X X X X X X X SK Photography9 X X10 X11 X X10 X X10 X X X X Study Medication Application12 X X X Subject Satisfaction Assessment13 X X X X X X Concomitant Therapies14 X X X X X X X X X X X Adverse Events15 X X X X X X X X X X 1Subject inclusion/exclusion criteria will be reassessed prior to enrollment during Visit 2. 2Investigational sites will assign a unique five-digit subject identifier to each subject at Visit 1, formatted as NN-NNN where the first 2 digits are the site number, and the final 3 digits are the subject number that must be assigned in ascending numerical order (using leading zeroes, as appropriate). This subject identifier will be used in all study documentation for the duration of the study. 3Each subject’s skin must be assessed during Visit 1 using the Xxxxxxxxxxx Skin Type Assessment. Refer to Table 6 for the scale. 4Vital signs [including temperature, pulse, respiratory rate, blood pressure, height and weight (Visit 1 only)] will be measured by a qualified staff member at Visit 1, Visit 2, Visit 5, Visit 7 Visit 10, and Visit 11. 5Prior medications/therapies will be collected for a time-period of 13 days prior to Visit 1. Refer to Section 8.4 for a list of permitted and restricted concomitant m...
Sample 1

Related to Dose Adjustment Criteria

  • Additional RO Review Criteria (1) In addition to the requirements in Subparagraph 34A, the RO must:

  • ECONOMIC PRICE ADJUSTMENT is the adjustment to the Aircraft Basic Price (Base Airframe, Engine and Special Features) as calculated pursuant to Exhibit D.

  • Non pre-priced Adjustment Factor To be applied to Work deemed not to be included in the CTC but within the general scope of the work:

  • Selection Criteria Each Contract is secured by a new or used Motorcycle. No Contract has a Contract Rate less than 1.00%. Each Contract amortizes the amount financed over an original term no greater than 84 months (excluding periods of deferral of first payment). Each Contract has a Principal Balance of at least $500.00 as of the Cutoff Date.

  • Long Term Cost Evaluation Criterion # 4 READ CAREFULLY and see in the RFP document under "Proposal Scoring and Evaluation". Points will be assigned to this criterion based on your answer to this Attribute. Points are awarded if you agree not i ncrease your catalog prices (as defined herein) more than X% annually over the previous year for years two and thr ee and potentially year four, unless an exigent circumstance exists in the marketplace and the excess price increase which exceeds X% annually is supported by documentation provided by you and your suppliers and shared with TIP S, if requested. If you agree NOT to increase prices more than 5%, except when justified by supporting documentati on, you are awarded 10 points; if 6% to 14%, except when justified by supporting documentation, you receive 1 to 9 points incrementally. Price increases 14% or greater, except when justified by supporting documentation, receive 0 points. increases will be 5% or less annually per question Required Confidentiality Claim Form Required Confidentiality Claim Form This completed form is required by TIPS. By submitting a response to this solicitation you agree to download from th e “Attachments” section, complete according to the instructions on the form, then uploading the completed form, wit h any confidential attachments, if applicable, to the “Response Attachments” section titled “Confidentiality Form” in order to provide to TIPS the completed form titled, “CONFIDENTIALITY CLAIM FORM”. By completing this process, you provide us with the information we require to comply with the open record laws of the State of Texas as they ma y apply to your proposal submission. If you do not provide the form with your proposal, an award will not be made if your proposal is qualified for an award, until TIPS has an accurate, completed form from you. Read the form carefully before completing and if you have any questions, email Xxxx Xxxxxx at TIPS at xxxx.xxxxxx@t xxx-xxx.xxx

  • Power Factor Design Criteria Developer shall design the Large Generating Facility to maintain an effective power delivery at demonstrated maximum net capability at the Point of Interconnection at a power factor within the range established by the Connecting Transmission Owner on a comparable basis, until NYISO has established different requirements that apply to all generators in the New York Control Area on a comparable basis. The Developer shall design and maintain the plant auxiliary systems to operate safely throughout the entire real and reactive power design range. The Connecting Transmission Owner shall not unreasonably restrict or condition the reactive power production or absorption of the Large Generating Facility in accordance with Good Utility Practice.

  • Long Term Cost Evaluation Criterion 4. READ CAREFULLY and see in the RFP document under "Proposal Scoring and Evaluation". Points will be assigned to this criterion based on your answer to this Attribute. Points are awarded if you agree not increase your catalog prices (as defined herein) more than X% annually over the previous year for the life of the contract, unless an exigent circumstance exists in the marketplace and the excess price increase which exceeds X% annually is supported by documentation provided by you and your suppliers and shared with TIPS, if requested. If you agree NOT to increase prices more than 5%, except when justified by supporting documentation, you are awarded 10 points; if 6% to 14%, except when justified by supporting documentation, you receive 1 to 9 points incrementally. Price increases 14% or greater, except when justified by supporting documentation, receive 0 points. increases will be 5% or less annually per question Required Confidentiality Claim Form Required Confidentiality Claim Form This completed form is required by TIPS. By submitting a response to this solicitation you agree to download from the “Attachments” section, complete according to the instructions on the form, then uploading the completed form, with any confidential attachments, if applicable, to the “Response Attachments” section titled “Confidentiality Form” in order to provide to TIPS the completed form titled, “CONFIDENTIALITY CLAIM FORM”. By completing this process, you provide us with the information we require to comply with the open record laws of the State of Texas as they may apply to your proposal submission. If you do not provide the form with your proposal, an award will not be made if your proposal is qualified for an award, until TIPS has an accurate, completed form from you. Read the form carefully before completing and if you have any questions, email Xxxx Xxxxxx at TIPS at xxxx.xxxxxx@xxxx-xxx.xxx 8 Choice of Law clauses with TIPS Members If the vendor is awarded a contract with TIPS under this solicitation, the vendor agrees to make any Choice of Law clauses in any contract or agreement entered into between the awarded vendor and with a TIPS member entity to read as follows: "Choice of law shall be the laws of the state where the customer resides" or words to that effect. 9

  • Performance Measurement Satisfactory performance of this Contract will be measured by:

  • Evaluation Criteria 5.2.1. The responses will be evaluated based on the following: (edit evaluation criteria below as appropriate for your project)

  • Equitable Adjustment Trading volume amounts, price/volume amounts and similar figures in the Transaction Documents shall be equitably adjusted (but without duplication) to offset the effect of stock splits, similar events and as otherwise described in this Agreement and Warrants.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!